ArticleFrontiers in neuroscience2026
Study on the improvement of electroencephalogram signal characteristics in stroke patients by edaravone dexborneol.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effects of edaravone dexborneol injection on the cortical electroencephalogram (EEG) signal characteristics in patients with acute ischemic stroke (cerebral infarction) and evaluate its mechanism in promoting neurological recovery from a neurophysiological perspective. Methods: A total of 80 patients with acute anterior circulation cerebral infarction, treated at the Department of Neurology, Second Hospital of Hebei Medical University, were randomly divided into the control group (routine treatment) and the experimental group (routine treatment + edaravone dexborneol). EEG data were collected at rest for both groups at baseline (T0) and 7 days after treatment (T1). The collected EEG signals were pre-processed, and the relative power spectral densities in the delta, theta, alpha, and beta frequency bands of the affected hemisphere were calculated and compared between the two groups. Additionally, signal complexity (Lempel-Ziv complexity, LZC) and approximate entropy (ApEn) were assessed. Neurological deficits were evaluated using the National Institutes of Health Stroke Scale (NIHSS), and the correlation between EEG characteristics and NIHSS scores was analyzed. Results: After treatment, compared to the control group, the experimental group showed a significant decrease in the relative power in the delta frequency band and a significant increase in the relative power in the alpha and beta frequency bands in the affected hemisphere ( Conclusion: Treatment with edaravone dexborneol can effectively improve abnormal EEG patterns in patients with cerebral infarction, characterized by reduced slow-wave activity and increased fast-wave activity and EEG complexity/orderliness. These beneficial changes in EEG characteristics are synchronized with clinical neurological recovery, suggesting that the drug may promote the reshaping and functional reorganization of neural networks by reducing oxidative stress, neuroinflammation, improving cerebral microcirculation, and enhancing neuronal metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.